ABBV vs BMY
By Alex · Tickerpine
AbbVie Inc. vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | BMY |
|---|---|---|
| Price | $253.35 | $57.52 |
| Market cap | $447.62B | $117.46B |
| P/E ratio | 123.6 | 16.1 |
| ROE | — | 38.73% |
| Profit margin | 5.79% | 15.01% |
| Revenue growth | 12.40% | 2.60% |
| Dividend yield | 2.73% | 4.38% |
| Beta | 0.31 | 0.24 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs BMY in plain English
- ABBV is the bigger company — about 3.8× the market cap of BMY.
- BMY is cheaper on earnings (P/E 16.1 vs 123.6).
- ABBV is growing revenue faster (12% vs 3%).
- BMY has the higher dividend yield (4.38% vs 2.73%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.